Navigation Links
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
Date:2/17/2009

NEW HAVEN, Conn., Feb. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its lead oncology therapeutic Onrigin (laromustine) Injection as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The Company has requested a priority review for the application and, if granted, Onrigin could receive approval for this indication in the second half of 2009.

Alan Kessman, Chief Executive Officer, commented, "This NDA filing is a significant milestone for Vion and for the Onrigin clinical development program. Acute myeloid leukemia is a devastating disease, and patients and their physicians are seeking new treatment options that can provide the opportunity for achieving a complete response." He concluded, "We are excited to be taking this major step towards achieving FDA approval for Onrigin."

The Onrigin NDA submission is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these patients had two or more risk factors that predicted for a poor prognosis. The Company presented data on this group of patients in a poster at the American Society of Hematology (ASH) Annual Meeting in December 2008.

Dr. Frank Giles, Chief of the Division of Hematology and Medical Oncology and Deputy Director of the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio commented, "If approved, Onrigin would represent an important new treatment option for elderly AML patients, many of whom now have no effective therapeutic option
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
7. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
8. Tigris Pharmaceuticals Files IND Application for GGTI-2418
9. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
10. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
11. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Medicine, recently presented new data on the relationship of genetics and hypertension at ... Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... ROCHESTER, N.Y., March 24 China,s State ... of the pioneering Lucid VivaScope(R),reflective confocal microscope ... Jay,Eastman, CEO of Lucid, a Rochester, New ... providing improved care for dermatology,patients., Lucid,s ...
... CRY ),a biomaterials, medical device and tissue ... SG pulmonary human heart,valve since the product was ... February. The procedure was performed on a patient ... The CryoValve SG is processed with,the Company,s proprietary ...
... SANTA CLARA, Calif., March 24 Finesse Solutions, ... life sciences process,applications, announces the release of TruFluor(TM), ... Interphex in Philadelphia on March,26, 2008., The ... solution consisting of a disposable sheath, an optical ...
Cached Biology Technology:Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 2Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 3CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve 2CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve 3Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter 2
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... led to an epidemic of obesity and type-2 diabetes in ... University that are due to be published in the 5 ... of Science and also in the PNAS early online edition ... expands the known taxonomic breadth of metabolic disease and suggests ...
... basis for eventual treatment, neurology researchers have shown that ... that helps keep brain activity in balance. The resulting ... underlying reason for seizures and memory defects experienced by ... , "A traumatic brain injury occurs to someone in ...
... have discovered that autoimmunity can be triggered in the thymus, ... fail to recognize just one of the body's thousands of ... that autoimmunity can start in this cradle of the immune ... emerge, such as the pancreas in the case of type ...
Cached Biology News:Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5How brain injury leads to seizures, memory problems 2Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
... Mass Directed Auto Purification software, a ... system designed for automated compound isolation ... and pharmaceutical discovery programs. The system ... high throughput mass directed auto purification ...
... Anti-M13 polyclonal antibody was derived from ... phage particles.Recombinant protein domains such as antibody ... protein pIII and displayed on phage using ... system utilized in the Ph.D. libraries. Anti-M13 ...
... Ligation Kit enables ligation of ... in just 5 min at ... the DNA concentration, either circular ... (high DNA concentration) ligation products ...
... catalyzes the transfer of the ... 5-terminus of polynucleotides or to ... The enzyme, purified from recombinant ... to phosphorylate RNA, DNA and ...
Biology Products: